Skip to Content
Merck

Key Documents

View All Documentation

SML1099

Roflumilast

≥98% (HPLC), powder, phosphodiesterase 4 PDE4 inhibitor

Synonym(s):

3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide, 3-Cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-dichloropyrid-4-yl]-benzamide

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C17H14Cl2F2N2O3
CAS Number:
162401-32-3
Molecular Weight:
403.21
UNSPSC Code:
41106305
PubChem Substance ID:
329825476
NACRES:
NA.77
MDL number:
MFCD00938270
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Roflumilast, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

−20°C

SMILES string

ClC1=CN=CC(Cl)=C1NC(C2=CC=C(OC(F)F)C(OCC3CC3)=C2)=O

InChI

1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)

InChI key

MNDBXUUTURYVHR-UHFFFAOYSA-N

Gene Information

human ... PDE4A(5141), PDE4B(5142), PDE4C(5143), PDE4D(5144)

Application

Roflumilast has been used to evaluate its effect on acute lung inflammation and chronic lung changes in models of cigarette exposure in mice. It is also used to investigate its therapeutic potential to ameliorate primary blast-induced deficits in long-term potentiation (LTP).

Biochem/physiol Actions

Roflumilast is a highly potent, orally active, and selective phosphodiesterase 4 (PDE4) inhibitor with an IC50 of 0.8 nM. Roflumilast has anti-inflammatory properties and is used clinically to treat COPD.
Roflumilast is a highly potent, orally active, and selective phosphodiesterase 4 (PDE4) inhibitor.

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Still not finding the right product?

Explore all of our products under Roflumilast

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000526507
0000526513
0000526507
0000526513
0000512436

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Innocence Harvey et al.
Obesity (Silver Spring, Md.), 31(7), 1859-1870 (2023-05-31)
Prescription glucocorticoid (GC) use is widespread across developed countries for the treatment of several inflammatory conditions. Elevated GCs are known to promote lipolysis and metabolic disorders. An extract of Artemisia scoparia (SCO) has been shown to reduce lipolysis and promote
Fernando J Martinez et al.
Lancet (London, England), 385(9971), 857-866 (2015-02-17)
Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. Its effect in patients using fixed combinations of inhaled corticosteroids and longacting β2 agonists is unknown. We postulated that roflumilast would reduce exacerbations in patients with severe chronic obstructive
Phosphodiesterase-4 inhibition restored hippocampal long term potentiation after primary blast.
Vogel E W, et al.
Experimental Neurology, 293, 91-100 (2017)
View All Related Papers